Everyone here blames the drug. Half the time it is the appointment schedule, not the molecule.

Careful with attribution. You changed the timing, the dose and the season. That is three variables.

Access to mugs should be on the clinical questionnaire.

Most of what is called evidence here is one person, one vial, one month. Not on retatrutide but the pattern is familiar.

Stupid question: how do you know whether what is in the vial matches the label at all?